Blocking the partnership between regulatory T cells (Tregs) and dendritic cells may increase the efficacy of immunotherapy for pancreatic cancer, a new study suggests.
In the study, published in Cell Reports, investigators examined pancreatic ductal adenocarcinoma (PDA). Prior studies have shown a link between the early buildup of Tregs in tumors and a reduction in survival. Read more . . .